Promising Clinical Data and Strategic Advancements Drive Buy Rating for Krystal Biotech

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech (KRYS – Research Report), with a price target of $240.00.

Joseph Pantginis has given his Buy rating due to a combination of factors related to Krystal Biotech’s promising clinical data and strategic advancements. The company presented encouraging results from its Phase 1/2 study of the inhaled KB707, which targets solid tumor malignancies in the lungs. The study showed a notable objective response rate, with partial responses in a significant portion of the evaluable patients, and the responses were durable with median duration of response and progression-free survival not yet reached.
Additionally, the safety profile of KB707 was favorable, with adverse events consistent with expectations and no severe cases reported. The ongoing expansion of the study to include combination therapies with anti-PD-1 and chemotherapy could further enhance the therapeutic potential of KB707. These factors collectively support the positive outlook on Krystal Biotech’s stock, leading to the Buy rating.